<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05613296</url>
  </required_header>
  <id_info>
    <org_study_id>ITP1122</org_study_id>
    <nct_id>NCT05613296</nct_id>
  </id_info>
  <brief_title>Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP</brief_title>
  <official_title>Real World Evaluation Among Italian Centers of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With Immune Thrombocytopenia (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective and prospective multicenter observational study with the aim to&#xD;
      evaluate the real-life use of Fostamatinib in adult patients with chronic ITP, refractory to&#xD;
      other treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective and prospective multicenter observational study with the aim to&#xD;
      evaluate the real-life use of Fostamatinib in adult patients with chronic ITP, refractory to&#xD;
      other treatments.&#xD;
&#xD;
      All patients who received at least one dose of Fostamatinib between October 1st, 2021 and&#xD;
      April 1st, 2023 outside interventional clinical trials in Italy in the participating centers&#xD;
      will be invited to participate in the study. Every patient will be observed for at least 6&#xD;
      months until October 1st, 2023.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2023</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of ITP patients who receive Fostamatinib</measure>
    <time_frame>6 months</time_frame>
    <description>effectiveness evaluation of fostamatinib</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">47</enrollment>
  <condition>ITP - Immune Thrombocytopenia</condition>
  <condition>Chronic ITP</condition>
  <condition>Refractory ITP</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>All patients being observed during the study duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Patients with Chronic ITP, refractory to other treatment who received at least one dose of Fostamatinib outside clinical trials in Italy will be enrolled and observed for at least 6 months.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All adult ITP patients, refractory to other treatment, who received at least one dose of&#xD;
        Fostamatinib between October 1st, 2021 and April 1st, 2023 outside interventional clinical&#xD;
        trials in Italy in the participating Centers will be invited to participate in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with chronic ITP who are refractory to other treatments and who received&#xD;
             Fostamatinib according to standard clinical practice between October 1st, 2021 and&#xD;
             April 1st, 2023&#xD;
&#xD;
          2. Age greater or equal to 18 years at the treatment start&#xD;
&#xD;
          3. Signed written informed consent document (if feasible) according to ICH/EU/GCP and&#xD;
             national local laws&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications or hypersensitivity to Fostamatinib, its active substance or any of&#xD;
             its excipients&#xD;
&#xD;
          2. Patients participating in an interventional clinical trial at the time of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francescp Zaja</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ematologia ASUGI Trieste</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <phone>0670390528</phone>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <phone>0670390514</phone>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 4, 2022</study_first_submitted>
  <study_first_submitted_qc>November 4, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>January 12, 2023</last_update_submitted>
  <last_update_submitted_qc>January 12, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

